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A potential role for the long-chain acyl-CoA synthetase family member 1 (ACSL1)
in the immunobiology of sepsis was explored during a hands-on training workshop.
Participants first assessed the robustness of the potential gap in biomedical knowledge
identified via an initial screen of public transcriptome data and of the literature associated
with ACSL1. Increase in ACSL1 transcript abundance during sepsis was confirmed in
several independent datasets. Querying the ACSL1 literature also confirmed the absence
of reports associating ACSL1 with sepsis. Inferences drawn from both the literature (via
indirect associations) and public transcriptome data (via correlation) point to the likely
participation of ACSL1 and ACSL4, another family member, in inflammasome activation
in neutrophils during sepsis. Furthermore, available clinical data indicate that levels of
ACSL1 and ACSL4 induction was significantly higher in fatal cases of sepsis. This
denotes potential translational relevance and is consistent with involvement in pathways
driving potentially deleterious systemic inflammation. Finally, while ACSL1 expression was
induced in blood in vitro by a wide range of pathogen-derived factors as well as TNF,
induction of ACSL4 appeared restricted to flagellated bacteria and pathogen-derived
TLR5 agonists and IFNG. Taken together, this joint review of public literature and omics
data records points to two members of the acyl-CoA synthetase family potentially
playing a role in inflammasome activation in neutrophils. Translational relevance of these
observations in the context of sepsis and other inflammatory conditions remain to
be investigated.
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INTRODUCTION
Long-chain acyl-CoA synthetases (ACSLs) are essential enzymes that activate fatty acids (FA)
by converting them to FA acyl-CoA esters. This activation is required for both synthesis of
cellular lipids, such as triacylglycerol (TAG), phospholipids, and cholesterol esters as part of
anabolic lipid metabolism, as well as their degradation via β-oxidation as part of catabolic lipid
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metabolism (1). Deregulation of FA metabolism is frequently
encountered across metabolic diseases and carcinogenesis (2–
4). ACSLs play a role in the pathogenesis to fatty liver disease,
obesity, atherosclerosis, diabetes, neurological disorders, and
specific types of cancer (4). Five ACSL family members have been
described, ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6, which
are encoded by separate genes (5). Each of these enzymes have
distinct substrate specificities, tissue specific expression patterns,
and different subcellular localizations (1).
Involvement of ACSL1 in immunological processes was
examined in the context of a hands-on workshop which used
available public omics data as source of training material. ACSL1
was selected among a pool of gene candidates on the basis, on
one hand of its upregulation in neutrophils following in vitro
exposure to septic plasma, and on the other of the absence or
limited number of literature reports linking it with neutrophil
immunobiology or the pathogenesis of sepsis.
Focusing a review on a research area which has been
overlooked is inherently challenging given the lack of good
published reports on the topic in question. However, exploring
such gaps in knowledge and attempting to define avenues for
future research remains a useful endeavor. Furthermore, publicly
available omics data were employed as a means to, at least in part,
overcome the absence of publication on the topic being covered.
Indeed, in addition to initially permitting identification of the
knowledge gap this approach also provided opportunities: (1) to
confirm initial observation across independent datasets, (2) to
draw inferences from co-expression (guilt by association). While
this review does not address the identified knowledge gap in a
way a research paper would, it permits to bring such a gap to the
attention of the community in a timely manner and delineates
potential avenues for future investigations.
KNOWLEDGE GAP ASSESSMENT
As described in a recent review, workshop participants for the
first of three “collective omics data” (COD) training modules
currently under development are tasked to assess potential gaps
in biomedical knowledge for a given gene candidate (6).
It is in this context that ACSL1 was selected among a larger
pool of candidate genes for which transcript abundance was
elevated in neutrophil cultures exposed in vitro to plasma of
septic patients (7) [Figure 1 and link to data browsing web
application (8)]. One of the first steps consisted in evaluating the
robustness of this observation by looking up ACSL1 expression
profiles across datasets which were deemed suitable for this
validation step (Figure 2). Suitability in this case was judged by
the workshop participants based on experimental/study design
(i.e., inclusion of sepsis cases and suitable controls). Importantly,
in order to avoid selection bias, studies were identified for
validation prior to accessing the ACSL1 transcriptional profiles
to verify differential expression. Since another member of the
ACSL family, ACSL4, was also among the candidates which
passed our selection criteria it was decided to attempt to
confirm differential expression across multiple sepsis datasets.
Upregulation of ACSL1 and ACSL4 could be confirmed in both
of the validation datasets deposited by Khaenam et al. (GSE49756
and GSE49757). Furthermore, significant increase in abundance
for both of these members of the ACSL family were observed in
four of the six independent datasets. These included whole blood
and PBMCs samples collected from adult or pediatric sepsis
subjects and appropriate uninfected controls, run on illumina or
affymetrix array platforms and in the context of studies carried
out on different continents (as indicated on Figure 2: middle and
bottom panels).
With the increase in ACSL1 abundance confirmed in
multiple independent sepsis datasets, the next step consisted in
interrogating the literature for current knowledge about its role
in this setting. Workshop participants were tasked to build a
PubMed query capturing the pool of publications that constitutes
the ACSL1 literature.
The query is comprised of all official names, symbols and
aliases recorded for ACSL1 in the NCBI entrez gene database,
OMIM and swissprot databases. The [tw] argument is added
to force PubMed to perform the search as specified [(tw) =
text words: thus restricting the search to text included in tiles
and abstracts]:
“ACSL1” [tw] OR “Acyl-CoA Synthetase Long Chain Family
Member 1” [tw] OR “Acyl-CoA Synthetase Long Chain Family
Member 1” [tw] OR “Fatty-Acid-Coenzyme A Ligase, Long-
Chain 2” [tw] OR “Long-Chain Fatty-Acid-Coenzyme A Ligase 1”
[tw] OR “Long-Chain-Fatty-Acid–CoA Ligase 1” [tw] OR “Long-
Chain Fatty Acid-CoA Ligase 2” [tw] OR “Long-Chain Acyl-CoA
Synthetase” [tw] OR “Long-Chain Acyl-CoA Synthetase 1” [tw] OR
“Long-Chain Acyl-CoA Synthetase 2” [tw] OR “Lignoceroyl-CoA
Synthase” [tw] OR “Palmitoyl-CoA Ligase 1” [tw] OR “Palmitoyl-
CoA Ligase 2” [tw] OR “Acyl-CoA Synthetase 1” [tw] OR “LACS 1”
[tw] OR “LACS 2” [tw] OR “LACS-1” [tw] OR “LACS-2” [tw] OR
“FACL2” [tw] OR “FACL1” [tw] OR “LACS1” [tw] OR “LACS2”
[tw] OR “ACS1” [tw] OR “LACS” [tw] OR “Fatty-Acid-Coenzyme
A Ligase, Long-Chain 1” [tw] OR “Palmitoyl-CoA Ligase 1” [tw]
AND (acyl [tw] OR CoA [tw] OR fatty [tw] OR synthetase [tw] OR
Palmitoyl [tw] OR ligase [tw] OR ACSL1 [tw])
This PubMed query returned a total of 625 articles as of May of
2019. The query argument, following the boolean “AND” was
introduced to minimize the rate of false positives. It excluded
irrelevant articles including for instance the ACSL1 alias “LACS”
but referring to something entirely different, such as “Laser-
Assisted Cataract Surgery” (LACS), or “Low molecular weight
Aromatic Compounds” (LACs).
Next, the degree of novelty of the observation reported in
Figure 1 was determined by interrogating the ACSL1 literature
(i.e., assessment of a potential gap in biomedical knowledge).
For this purpose, the representation in the ACSL1 literature of
relevant topics was examined.
The study that served as a starting point for this review
consisted in exposing neutrophils in vitro to septic plasma,
resulting in significant increase in levels of abundance of ACSL1
transcripts. Therefore, the most relevant topics selected for the
assessment of potential gaps in biomedical knowledge were
“sepsis” and “neutrophils.”
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FIGURE 1 | ACSL1 is upregulated by septic plasma. Abundance of ACSL1 transcripts was measured by microarray in neutrophils exposed in vitro for 6 h to plasma
from uninfected control subjects or from patients with sepsis [from a dataset deposited in GEO by Khaenam et al. with unique identifier GSE49755 (7)]. Neutrophils
were obtained from two different healthy donors, each exposed to the same set of plasma samples which consisted in plasma from 6 uninfected controls and 12
septic patients. Differences between groups were statistically significant (**p < 0.01), and confirmed in two independent test sets from the same study (GSE49756,
GSE49757). ACSL1 profiles from all three datasets can be accessed via the GXB data browsing application: (8–10). Design elements in this and subsequent figures
obtained from http://www.clker.com/ (eppendorf tube) and https://www.vecteezy.com (red cross, DNA helix, cell).
One of the 625 articles constituting the ACSL1 literature
contained the keywords “sepsis,” “septic,” “septicemia,” or
“septiceamia,” This work examined responses to endotoxin
treatment in mice and made reference to sepsis for context
without actually studying septic animals (17). The authors report
a decrease in ACSL1 expression in liver and adipose tissues
in mice treated by LPS. Three articles contained the keywords
“neutrophil” or “neutrophils” in its title or abstract. These
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reports, which were all published in the early 1990s, employed an
ACSL1 inhibitor, triacsin C, to investigate its role in regulating
production of various factors, including superoxide anions,
which mediate in part neutrophils microbicidal activity, or
eicosanoids, which are oxidized fatty acids possessing pleiotropic
signaling properties (18–20).
It was thus possible to conclude at this stage:
- First that the increase in ACSL1 abundance observed in
neutrophils exposed in vitro to septic serum is a relevant
phenomenon in vivo, since it was also increased in the blood
of septic patients.
- Second, that this phenomenon can be considered to be robust
since it was observed in multiple studies across various clinical
and study settings.
- Third, that an increase in ACSL1 expression has not been
reported in the literature in the context of sepsis to date. And
that a role for ACSL1 in neutrophil immunobiology has been
described, but not in the context of sepsis. Furthermore, it is
an area of research which has been inactive for at least the past
two decades.
The next steps consisted in bringing additional context via a
general review of the literature retrieved for ACSL1 and four
other members of the long chain acyl-CoA synthetase family.
Several reference transcriptome datasets which are available
publicly were also consulted in order to complete this picture.
REVIEW OF ACSL FAMILY MEMBERS
FUNCTION AND ROLE IN DISEASE
In order to draw inferences on the possible role played
by ACSL1 in sepsis, context was obtained by conducting a
background literature review. As a first step, each of the workshop
participants were tasked to retrieve literature for one of the
five known members of the family of human ACSL genes.
Once they had optimized PubMed queries designed to retrieve
the literature of each respective family members, keywords
identified “manually” in titles of articles were recorded and
categorized (categories included for instance: disease, tissue, cell
type, biomolecule, biological process). Recording the frequency
at which those keywords occurred in the literature allowed in
turn the identification of the main research themes for each
family member.
Furthermore, tissue-specific expression of ACSL family
members was looked up in BioGPS, a publicly accessible data
browsing portal which comprises several reference transcriptome
datasets (21). Relative abundance of ACSL family members
in human tissues is shown in Supplementary Figure 1 and
discussed below.
ACSL1
Main themes for ACSL1 identified via profiling of its literature
were: lipid metabolism, fatty acid uptake, insulin, and muscle.
ACSL1 is the main ACSL family member expressed in the
liver (22). Substrate specificity is highest for saturated and
monounsaturated FA that are 16–18 carbons in length (23).
Overexpression of ACSL1 in rat hepatocytes increased oleate
incorporation into diacylglycerol and phospholipids (24). Liver-
specific knockout reduced TAG synthesis and FA oxidation (22).
ACSL1 expression has also been described in skeletal muscle
(25), prostate (26), and adipose tissue (27). In mice, ACSL1 was
specifically required for FA beta-oxidation in both muscle and
adipose tissue (25, 27). In human adipocytes, ACSL1 expression
has been associated with increased lipid content and insulin
sensitivity (28). Additionally, ACSL1 knockdown in adipocytes
resulted in upregulation of proinflammatory chemokine (C-C
motif) ligand 2 (CCL2) and chemokine (C-C motif) ligand 5
(CCL5) and the macrophage associated surface antigen cluster
of differentiation 14 (CD14) (28). Although ACSL1 was found
to localize to mitochondria, a role for FA uptake in adipocytes
has been proposed by the mechanism of metabolic trapping
(29). A similar role has been described in human hepatoma
cells (30). Upregulation of ACSL1 has been observed in various
cancer types, including breast cancer (31), colon cancer (32), and
liver cancer (30, 33, 34). Interestingly, aspirin down-regulates
ACSL1 expression in liver cancer cells and suppresses abnormal
lipid metabolism via inhibition of NFκB-ACSL1 signaling (34).
Consistently with reports from the literature, BioGPS profiles
indicated predominant expression of ACSL1 in liver and prostate
tissue (22, 26) (Supplementary Figure 1). Interestingly, it is also
by far the member of the ACSL family that is most highly
expressed in blood, which is another indication of the more
prominent role ACSL1 might play in immunity in comparison
with other ACSLs.
ACSL3
Main themes for ACSL3 identified via profiling of its literature
were: lipid droplet, liver, and goose fatty liver. Expression of
ACSL3 has been described in various tissues including the
brain (35), pancreatic islet cells (36), upper small intestine
(37), vascular smooth muscle cells (38), liver (39–41), and fetal
liver (42). Transcriptome data available via the BioGPS portal
and depicted in Supplementary Figure 1 shows ACSL3 as the
member of the family with the highest degree of restriction to
the CNS. ACSL3 is typically found on cellular lipid droplets
and the endoplasmic reticulum (ER) (43). Different functions
of ACSL3 have been reported across these different tissue types.
As ACSL3 moves from the ER to newly formed lipid droplets
upon exogenous FA treatment, a role for lipid synthesis has been
proposed (44). In pancreatic cells, ACSL3 localized to insulin
secretory granules and ACSL3 knockdown inhibited glucose-
stimulated insulin release (36). In vascular smooth muscle cells,
NFκB-ACSL3 signaling was identified to mediate palmitic acid
induced osteoblastic differentiation (38). In the brain, activation
of long-chain FA by ACSL is required for FA incorporation in
signaling molecules as well as structural components, such as
myelin (45).
ACSL4
Main themes for ACSL4 identified via profiling of its
literature were: fatty acid metabolism and arachidonic acid
metabolism/regulation. ACSL4 gene expression has mostly been
reported in the adrenal gland, liver, and adipose tissue (1, 46, 47).
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FIGURE 2 | Abundance of ACSL1 and ACSL4 transcripts is significantly increased in the context of sepsis in five out of seven datasets. Fold changes in abundance
of ACSL1 and ACSL4 is shown in sepsis vs. control groups across multiple datasets (7, 11–16). Each spot represents a single dataset, except for GSE49756/7 which
shows averaged values for the GSE49756 and GSE49757 series and that also comprises GSE49755 (Figure 1). The position of the spot on the vertical axis indicates
the corresponding fold change in abundance of ACSL1 (left) and ACSL4 (right). Spots are connected to dataset attributes (metadata). On the top panel attributes
relevant to the group comparisons that were performed are shown (indicating which groups are being compared and whether increase in ACSLs abundance are
statistically significant). On the middle and bottom panels additional attributes that describe the study populations and assays are shown.
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This is also consistent with the transcriptional profiling data
available via the BioGPS portal, which shows a predominance
of ACSL4 expression in fetal liver (Supplementary Figure 1).
Overexpression of this gene has previously been reported in
fetal liver in the Human Integrated Protein Expression Database
(48). However, a specific role for ACSL4 in fetal liver or liver
development has not been described. In adult liver ACSL1 is
the predominant form of long-chain acyl-CoA synthetase. The
substrate preference of ACSL4 is arachidonic acid (AA) and
eicosapentanoic acid (46). Next to a role for in AA metabolism
(46, 49–51), ACSL4 is involved in intracellular lipid storage (52),
and cholesterol transport from ER to the mitochondria (53). A
splice variant of ACSL4 was found in ER tubules of hippocampal
neurons in rats, and ACSL4 knockdown resulted in reduction
in dendritic spine density (54). In humans, ACSL4 has been
associated with X-linked mental retardation (55).
ACSL5
Main themes for ACSL5 identified via profiling of its literature
were: fatty acid uptake, mitochondrial metabolism, and physiology
of the intestine. ACSL5 is most abundantly expressed in the
small intestine, according to literature reports (1, 56–59) and
bioGPS ACSL5 expression profiles. Abundance increases along
the crypt-villus axis and is assumed to promote apoptosis in
enterocytes at the villus tip (60). Additionally, an anabolic
function of ACSL5 has been proposed, supporting FA uptake
by cells (39, 61). Interestingly, ACSL5 was found to be
associated with decreased Wnt signaling in normal human
intestinal tissues. Palmitolylation of Wnt2B mediated by ACSL5
results in accumulation of this protein to mitochondria and
consequently decreasedWnt activity (58). This finding illustrates
that next to regulation of lipid metabolism, ACSL family
members can also impact intracellular pathways by protein-
lipid modifications. Low expression of ACSL5 in colorectal
cancer has been associated with increased risk of tumor
recurrence (62).
ACSL6
Main themes for ACSL6 identified via profiling of its literature
were: fatty acid, DHA, and schizophrenia. Literature reports
ACSL6 to be almost exclusively expressed in the brain (61, 63–
65). This tissue restricted expression pattern suggests ACSL6
has a specific role in regulation of brain lipid metabolism.
ACSL6 was found to be required for enrichment of omega-
3 FA Docosahexaenoic acid that confers protection against
numerous neurological diseases (64). Correspondingly, genetic
polymorphism of the ACSL6 gene have previously been
associated with schizophrenia (66, 67). Reference transcriptome
data available via the BioGPS portal confirms restriction of
ACSL6 expression to the CNS, with highest levels observed
in the pineal gland, hypothalamus and prefrontal cortex.
However, expression levels are much lower than that of ACSL3
which minimizes ACSL6 contribution when considering overall
expression of ACSL family members across multiple tissues
(Supplementary Figure 1).
A REVIEW OF THE LITERATURE ON THE
ROLE OF ACSL FAMILY MEMBERS IN
IMMUNITY
Next focus of the literature and public transcriptome datasets
review shifted to examining the possible role of ACSL family
members in immunity in general, and more particularly in sepsis
and neutrophil immunobiology.
Monocytes and Macrophages
Whereas the regulation of ACSL family members has been
relatively well-described in solid organs, only a small number
of studies have examined the role of ACSLs in circulating
leukocytes. Compared to other immune cell types, ACSL family
members have been most frequently related to monocytes and
macrophages. This is consistent with a function of macrophages
in lipid metabolism that is mostly observed in the lung and liver
(68). Macrophages ingest LDL, VLDL, and oxidized lipoproteins
and digest them in the lysosome (69). Excess cholesterol is
exported from the cell to HDL, and free FA will be either
oxidized to generate energy or used for FA synthesis (68). The
requirement of FA oxidation or FA synthesis is dependent of
the macrophage’s phenotype (e.g., proinflammatory M1 or anti-
inflammatory M2) (70, 71). In fact, interfering with macrophage
FA oxidation induces phenotypical changes, suggesting that lipid
metabolism may control macrophage phenotype (72–74).
Inhibition of ACSL1, ACSL3, and ACSL4 by triacsin C,
significantly attenuated FA incorporation into diglyceride,
triglyceride, and phospholipids in human monocyte-derived
macrophages (75). ACSL4-specific inhibition by rosiglitazone
showed that this member has restricted effect on FA partitioning
to phospholipids, suggesting individual family members have
distinct functions (75). Similarly, triacsin C inhibited cytosolic
lipid droplet formation in mouse macrophages (76). Treatment
of mouse peritoneal macrophages with free FAs in the presence
of triacsin C reduced triglyceride synthesis, but increased
intracellular free FA levels, hereby inducing lipotoxicity (77). In
mouse macrophages, ACSL1 overexpression resulted in reduced
levels of the reverse cholesterol transporter ABCA1, suggesting a
role in regulating cholesterol efflux (78).
Upregulation of ACSL1 has been observed in response to
various stimuli and in diverse pathological conditions. Human
PBMC-derived macrophages infected with mycobacterium
tuberculosis had an increased expression of ACSL1 and increased
lipid droplet formation (79). In patients with type 1 diabetes,
ACSL expression was increased in monocytes and macrophages
(80). Gram-negative bacteria and LPS induce expression of
ACSL1 which correlated with increased phospholipids turnover
(81). Toll like receptor agonists were also found to promote
prolonged triglyceride retention that associated with increases
in ACSL1 (82, 83). Tyrosine kinase, an integral component of
the JAK-STAT pathway was found to affect protein expression of
ACSL4 in bone marrow-derived macrophages from mice (84).
Abundance of ACSL1 proteins has been found to be increased
in monocytes and macrophages displaying inflammatory
phenotypes (80, 85). ACSL1-deficient macrophages in a
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mouse model of diabetes, showed a marked reduction in
arachidonoyl-CoA levels. In these macrophages, beta-oxidation
and lipid accumulation were not impaired, suggesting a specific
role in arachidonoyl handling (86). ACSL1 expression in
macrophages associated with an inflammatory phenotype
characterized by upregulation of cytokines IL-1b, IL-6, and
CCL2, most likely mediated by levels of arachidonoyl-CoA that
is required for eicosanoid production (80, 86). Another study
also demonstrated that ACSL1 expression effects inflammatory
activity of cultured human THP-1 macrophages. Both ACSL1
inhibition and knockdown by siRNA suppressed palmitate-
induced TNF-α expression. Eicosapentaenoic acid was shown to
have an anti-inflammatory effect through inhibition of ACSL1
expression (87).
Only few articles describe the potential roles for ACSL in
neutrophils. Evidence for the effects of ACSLs in neutrophils
dates back to the early 1990s and is derived from experiments
treating neutrophils with triacsin C, an ACSL inhibitor. In rat
neutrophils stimulated with A23187 or fMLP, pretreatment with
triacsin C upregulated platelet-activating factor. Inhibition of
ACSL resulted in inhibition of acylation of lyso-phospholipids,
enhancing in turn the supply of substrate for PAF synthesis
(18). The same group also found that ACSL is involved in the
acylation of arachidonic acid in rat neutrophils. Pretreatment
with triacsin C inhibited incorporation of arachidonic acid into
the cells and resulted to an increased release of arachidonic
acid metabolites (19). In human neutrophils, a more direct
relation between ACSL activity and neutrophil function was
found. Triacsin C inhibited generation of superoxide anion
and release of azurophilic granules by human neutrophils. As
reactive oxygen species (ROS), such as superoxide anion play
an important role in neutrophils protective mechanisms, these
findings suggest that ACSL activity is important for neutrophil
functions (88). A proposed reason for the requirement of acyl-
CoA in both neutrophil respiratory burst and the modulation of
neutrophil degranulation is that both processes would require
phospholipid synthesis (88, 89). In fact, more recently, a key
role for phospholipids has been described in increasing and
dampening of the production of ROS during the oxidative
burst (90).
Other Immune Cell Types
For other immune cell subsets, there is very limited evidence
for the function of ACSL. In NK-cells and B-cells, no articles
were found for either ACSL, and only two articles describe ACSL
in T-cells. An early study in murine thymoma and cytotoxic T
lymphocyte clones pointed to the presence of two distinct ACSL
family members in T-cells. The enzyme described in this study
and that is currently known as ACSL4 showed activity selective
for arachidonic acid (87). The second enzyme displayed broad
substrate specificity (87), implying expression of an additional
ACSL member in T cells (91). A few decades later, ACSL5
expression was reported to be higher in PBMCs of patients with
systemic lupus erythematosus compared to healthy controls. In
cultured Jurkat T-cells, ACSL5 expression was increased during
induced apoptosis, while siRNA downregulation of ACSL5
decreased induced apoptosis (92). These findings suggest a
potential role for ACSL5 in T-cell apoptosis.
A REVIEW OF PUBLIC REFERENCE
TRANSCRIPTOME DATASETS
Restriction of Expression of ACSL Family
Members in Blood Leukocytes
Additional context was obtained through a review of available
public reference datasets. A first dataset was accessed to verify
the restriction of ACSL family members across different blood
leukocyte populations. The dataset with ID GSE60424 deposited
in GEO by Linsley et al. comprises RNAseq profiles of six human
immune cell subsets isolated from healthy subjects, as well as
subjects with multiple sclerosis, ALS, Type 1 Diabetes or sepsis
(N = 19) (93). ACSL expression profiles for this dataset were
accessed using the GXB web application that permits interactive
browsing of gene expression data (94). Various dataset that are
available in NCBI’s Gene Expression Omnibus (GEO) have been
made accessible using this tool (95–99).
Interestingly, despite the limited number of publications
linking the activity of the long chain acyl-CoA synthetases to
immunity, members of the family were found to be robustly
expressed across various immune cell subsets (Figure 3). While
ACSL5 is the most highly expressed in CD8 and CD4 T-
cells, NK cells, and B-cells [GXB link (100)], neutrophils and
monocytes were found to mostly express ACSL1 [GXB link
(101)]. The most abundant family member in pre-erythrocytes is
ACSL6. Neutrophils have the overall highest expression of ACSL,
followed by monocytes, as represented by the size of the circle
diagrams in Figure 3. The relative expression profile of ACSLs
in monocytes is consistent with the identified articles using our
literature search for monocytes and macrophages. However, a
remarkably low number of articles describe the role of ACSL in
neutrophils, which is indicative of the presence of a current gap
in biomedical knowledge that remains to be filled.
Regulation of ACSL1 and ACSL4 in Blood
Cultivated With a Wide Range of Immune
Stimuli
A second reference dataset was accessed, which permits to
assess changes in levels of expression of ACSLs in blood in
response to a wide range of pathogen-derived and host-derived
immune stimuli. This dataset was contributed to GEO by
Obermoser et al. [GSE30101 (102)]. Overall, abundance of most
ACSL family members was found to be increased, except for
ACSL6. The highest rates of increase were observed for ACSL1,
ACSL4, as shown Figure 4. Patterns of induction were strikingly
different for those two ACSLs, with ACSL1 showing increases
in response to most purified pathogen derived molecules and
heat-killed bacteria, as well as the proinflammatory factor TNF
(103). ACSL4 induction was more narrowly restricted, showing
upregulation mostly in response to heat-killed bacteria and
purified components, such as PAM3 (TLR1/TLR2 ligand), and
flagellin (TLR5 ligand) (104). Notably, heat-killed Legionella
pneumophila, a flagellated gram negative bacteria, was the most
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FIGURE 3 | Restriction of expression of ACSL family members transcripts in human leukocyte populations. Relative transcript abundance levels for the 5 members of
the ACSL family are represented with cord plots for 7 different blood leukocyte populations. Expression data used to generate the plots were obtained from public
domain RNAseq dataset with accession ID GSE60424 (93), with the exception pre-erythrocytes expression data, which was obtained from the BioGPS dataset (21).
Each family member is represented by a different color: ACSL1 (red), ACSL2 (beige), ACSL4 (green), ACSL5 (blue), and ACSL6 (purple). The size of the circle is
proportional to relative expression levels of ACSLs. For instance, expression in neutrophils was about four times higher than in monocytes and ten times higher than in
other cell populations.
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FIGURE 4 | Induction of ACSL1 and ACSL4 expression in response to immune stimulation. The data presented here was generated by Obermoser et al. (GSE30101)
(102). The box plots show levels of abundance of ACSL1 and ACSL4 in whole blood of four healthy subjects incubated for 6 h. at 37◦C with 18 different immune
stimuli or left unstimulated. Conditions included Toll-like receptors agonists PAM3, Zymosan, Poly IC, E-LPS, Flagellin, R837, CpG Type A, heat-killed Escherichia coli
(HK E. coli), heat-killed Legionella pneumophila (HKLP), heat-killed Acholeplasma laidlawii (HKAL), and heat-killed Staphylococcus aureus (HKSA); live influenza A virus
(Flu) and live respiratory syncytial virus (RSV), and the host-derived immunostimulatory molecules IL18, TNF-α, IFN-α2b, IFN-β, IFN-γ.
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potent inducer of ACSL4 expression in this culture system. PAM3
[Pam (3) CSK (4)] is a strong stimulator of TLR5 expression in
neutrophils (105). Not shown on this figure but accessible via
the GXB are profiles of ACSL3 and ACSL5, which interestingly
in the case of ACSL3 is clearly restricted to stimulation via
Poly:IC (TLR ligand) and beta interferon (106). And in the
case of ACSL5 pattern of induction were to some extent similar
to those observed for ACSL4 (heat killed bacteria + PAM3 +
Flagellin) (107).
INFERRING THE ROLE OF ACSL1 IN
NEUTROPHILS IN THE CONTEXT OF
SEPSIS
Sepsis presents as a spectrum of systemicmanifestations resulting
from a pathogenic infectious process. Overt inflammation and
activation of the innate immune system is often mentioned
as one of the hallmarks of sepsis. But this response is also
accompanied by profound changes in metabolism homeostasis
and followed at later stages by potent immunosuppression,
marked reduction in inflammation and generally promotion of a
milieu favorable to tissue repair (108). During the early stages of
sepsis neutrophils play an important role in promoting microbial
clearance through microbicidal and pro-inflammatory effector
function. But they may present during the resolution phase of the
disease with altered cellular phenotype ranging from increased
lifespan, impaired migration to site of infection, and decreased
antimicrobial function (109–111).
As shown above the abundance of ACSL1 transcripts is
increased in sepsis in a wide range of study settings, but literature
describing mechanisms regulating its expression or its role in this
context is lacking.
The review of the literature and of public transcriptional
profiling data that we have conducted provides some clues with
regards to these aspects of the biology of ACSL1.
Regulation of ACSL1 Expression
The increase in abundance of ACSL1 transcripts observed in
whole blood of septic patients may be attributed on one hand to
the upregulation of its expression in vivo, but on the other hand it
may also be the result of an increase in the relative abundance in
blood of cellular populations preferentially expressing ACSL1. In
addition, it could of course also be the result of the combination
of both factors. The fact that an increase in ACSL1 abundance was
also observed after 6-h stimulation in vitro in blood cultures and
in neutrophil cultures suggests that changes in ACSL1 abundance
are likely to be at least in part attributable to regulation of gene
expression. In these in vitro blood cultures levels of expression
of ACSL1 were increased in response to whole bacteria or
purified pathogen-derived molecules as well as host-derived
inflammatory factors, such as TNF (Figure 5). Both pathogen-
and host-derived immunostimulatory molecules may be present
in septic plasma and contribute to the induction of ACSL1 and
ACSL4 expression observed in neutrophils cultures (Figure 1), as
well as in whole blood in vivo (Figure 2). Of potential interest
is the apparent differences in patterns of induction of ACSL1
and ACSL4, with as noted above a preferential induction of
ACSL4 by flagellin and the heat killed flagellated bacterium
Legionella pneumophila.
Another take on a potential mechanisms regulating ACSL1
expression originates from the fact that lipid metabolism is
frequently deregulated during sepsis, characterized by changes in
cholesterol, HDL and apolipoproteins in plasma of septic patients
(112–114). Evidence from an in vitro study suggests that exposure
to fatty acids significantly increases neutrophil adherence and
release of specific granules (115). Therefore, it is possible that
the changes in lipid content in plasma of septic patients could
be responsible for the observed increased expression of ACSL1 in
neutrophils, and consequently, altered neutrophil function.
A Potential Role for ACSL1 in Sepsis?
The actual role played by ACSL1 in sepsis and its contribution
to the pathophysiology of this condition remains to be defined.
In the meantime, some inferences can be drawn on the basis
of current knowledge of the role of ACSL1 in neutrophil and
monocyte/macrophage immunobiology on one hand and on
omics data co-expression analyses on the other hand.
Inferences Based on the Literature
As has been described in more details above, most of what
is currently known of the role of ACSL1 in neutrophils is
based on three articles published in the early 1990s (18–
20). These employed the inhibitor triacsin C to demonstrate
ACSL1 involvement in promoting production of superoxide
anions and degranulation, as well as decreasing production of
ecoisanoid and platelet activation factor. In the context of sepsis
production of reactive oxygen species by neutrophils accounts in
part for their microbicidal activity and contributes to pathogen
clearance (110). However, when oxidative stress levels increase
past a critical threshold cell apoptosis and end organ damage
may ensue.
A recent study in monocytes, which also employed triacsin
C, demonstrated a role for ACSL1 in mediating inflammatory
activity and phenotype following TNF stimulation (85). Another
very recent report was published demonstrating ACSL1 role
in driving production of IL1B in macrophages via regulation
of fatty acid metabolism in mitochondria (116). The same
study shows that ACSL1 expression is upregulated following
engagement of TLR4 in macrophages and, furthermore, that
knockdown of ACSL1 in macrophages results in decreased
NLRP3 inflammasome activation. Altogether this work points to
a pro-inflammatory role for ACSL1 in monocyte/macrophages,
possibly underlying inflammasome activation observed in
metabolic disorders characterized by high levels of circulating
saturated fatty acids. Data gathered from public repositories
presented in this review suggest that neutrophils may play a
greater role than previously recognized in this process.
Inferences Based on Co-expression Analysis
Co-expression analyses are a common means by which putative
function may be assigned to genes (referred to as “guilt
by association”). Here we took advantage of a repertoire of
transcriptional modules developed by our team on the basis
Frontiers in Immunology | www.frontiersin.org 10 October 2019 | Volume 10 | Article 2410
Roelands et al. ACSL1 in Sepsis
FIGURE 5 | Correlation matrix for a set of genes constituting a blood transcriptional module associated functionally with neutrophil-driven inflammation (M13.12). The
blood transcriptional module is part of a recently described repertoire constructed on the basis of co-expression across a 16 different immune/pathological states
(described in the text). The list of genes constituting this module (M13.12) comprised ACSL1. The matrix represents degree of correlation calculated for each gene pair
for the septic plasma neutrophil exposure dataset.
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FIGURE 6 | Clinical significance of increases in ACSL1, ACSL4, and Inflammasome genes in the septic plasma neutrophil exposure dataset. For this figure all three
datasets from this dataset series published as part of the work of Khaenam et al. were combined (see text for details). Fold changes over average of cells cultured with
medium only are shown. Available clinical information was used to assign sepsis subjects to either one of three groups: Recovered, Not improved and Dead.
Significance between the different groups is indicated above each graph with t-test *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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FIGURE 7 | Inferred role of ACSL1 in sepsis. The experimental context in which the increase in ACSL1 expression was initially observed is represented in the panel
above (GSE49755). Open questions include: #1 What are the factors in the plasma of septic patients that induce ACSL1 expression in neutrophils? #2 Which
signaling pathway is involved in regulation of ACSL1 following plasma exposure? #3 What is the role of ACSL1 in sepsis? Regarding question #1 (arrows down): briefly
as suggested by the data presented on Figure 4 ACSL1 is induced in blood by a wide range of pathogen-derived factors and ACSL4 by a narrower range of factors
(putatively attributed to the flagellated bacteria TLR5 agonist, flagellin). Regarding question #2 (oblique arrow): ACSL1 is known to contribute to the activation of
inflammasomes in macrophages, which in turn leads to release of proinflammatory factors (116). Based on differential and co-expression analyses we infer that it
might also be the case of ACSL4, for instance during responses to infection caused by flagellated bacteria. We also infer that ACSL-mediated inflammasome
activation operates in neutrophils and also in the context of sepsis, which are also points that remain to be established. Neutrophil contribution to the cytokine storm
observed during sepsis and subsequent immunopathology is well-documented. We thus assume that upregulation of ACSL1 observed during sepsis is of potential
clinical relevance. An assertion that is supported by differential levels of induction observed following exposure to plasma of subject who recovered vs. those who
died (Figure 6).
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of co-expression analysis of whole blood transcriptome profiles
obtained for 16 disease states across nearly 1000 subjects. Such
repertoires of co-expressed gene sets have been in use for over
10 years (102, 117), and the latest iteration used in this case is
described in a manuscript deposited on the BioRxiv pre-print
server (118). ACSL1 was included among a set of 55 transcripts
which were assigned the module identifier M12.13 (one of a
total of 381 modules). Functional profiling of this gene set
was performed via: (1) gene ontology enrichment, (2) Pathway
analysis (Ingenuity pathway analysis, Qiagen), (3) Literature
profiling (Literature lab, acumenta). In addition expression
levels were mapped for two different reference datasets: (1)
Blood leukocyte RNAseq dataset [GSE60424 (93)] and (2)
Hematopoeitic progenitor reference dataset [GSE24759 (119)].
Ontology, pathway and literature keyword enrichment all point
to a core group of genes constituting this module being strongly
associated with inflammation and in some cases more specifically
inflammasomes. Examples of genes most prominently associated
with inflammation, NOD-Like Receptor and Toll-like receptor
pathways include IRAK3, TLR5, IL18R1, IL18RAP, IL1RN,
as well as the inflammasomes molecules AIM2 and NLRC4.
Other annotations mention phagocytes and myeloid cells as
well as host-pathogen interaction. This fits well with leukocyte
transcript restriction data accessed for this set of 55 genes it
shows a markedly higher expression in neutrophils. Levels of
expression of those transcripts were also elevated in monocytes
in the context of sepsis (Supplementary Figure 2). More details
along with functional analysis reports for module M13.12 is
available via an interactive presentation (https://prezi.com/view/
pGdJTaNfTCaiJzJvkwif/). A high degree of correlation was also
observed among the transcripts forming M13.12 in the septic
plasma neutrophil exposure dataset used as a starting point
for this work (Figure 5). Correlation coefficient for ACSL1 and
NLRC4 for this dataset was 0.72.
Correlations were also measured for two “canonical”
inflammasome and fatty acid metabolism gene set (identified
via a knowledge-driven approach for the purpose of
offering targeted “RT2 profiler PCR arrays”). As shown on
Supplementary Figure 3 strong positive correlations were
observed between ACSL1 and nearly half of the transcripts that
belong to the inflammasome panel (including most notably
NLRC4, but also NLRP3, CASP1, CASP5, TXNIP). In the fatty
acid metabolism panel the strongest correlation observed was
with ACSL4, followed by PPA1, a member of the inorganic
pyrophosphatase family, and ACOT7, an Acyl-CoA thioesterase.
Taken together, inferences that could be drawn based on
both profiling of the literature and transcript co-expression
analysis confirm a likely role of ACSL1 in driving inflammasome-
mediated release of pro-inflammatory factors by neutrophils
during sepsis.
Clinical/Translational Implications
The burden of sepsis remains high, with poor outcomes observed
especially in developing countries. Despite several attempts
at developing drugs that would control overt inflammation
no immune-modifying treatment is currently available for
the management of sepsis (120). Contributing to a better
understanding of mechanisms underlying inflammatory
responses at play during sepsis should permit to refine targeting
strategies. Pinpointing the potential involvement of ACSL1 in
this process may thus prove of value. Choosing the timing of
such therapeutic intervention is particularly difficult given the
dynamic nature of the immune response during sepsis which is
characterized by an initial “cytokine storm” followed by a phase
during which the immune system becomes hyporesponsive.
The development of means to monitor the development of
the inflammatory response and guide treatment decision is
another gap worth addressing. It is however difficult to find
adequate longitudinal data that would permit to address this
point. Generating such data could be another worthwhile
endeavor, especially since levels of induction of ACSL1 following
neutrophil exposure to septic plasma were significantly higher
in response to plasma of patients who died from sepsis or did
not initially improve than in response to plasma of patients who
recovered (Figure 6). Similar differences were found for ACSL4,
NLRC4, and NLRP3.
Working Model and Follow on
Investigations
As stated in the introduction, the primary goals of this joint
review of the literature and public transcript profiling data
were first to explore a potential gap in biomedical knowledge
and second to obtain insights that may serve to guide
future experimentation. Inferences drawn from literature and
transcriptome data reviews are summarized in Figure 7. A role
has been very recently attributed to ACSL1 in inflammasome
activation and proinflammatory cytokine release in macrophages
(116). This was described by the authors as being mediated
via the formation of intracellular fatty acid crystals which
are causing lysosomal damage and in turn inflammasome
activation and IL1B release. But the fact that this pathway
may operate in neutrophils and in the context of sepsis has
not yet been recognized and it is something that co-expression
analyses presented in Figure 5 and Supplementary Figure 3
strongly support, and so does restriction of its expression among
blood leukocyte populations (Figure 3). Notably increase in
abundance were observed in vitro in response to septic serum
(Figure 1), but also in vivo in whole blood or neutrophil of septic
patients (Figure 2, Supplementary Figure 2). The transcriptome
profiling data that we have examined also suggest an involvement
of ACSL4 in activation of inflammasomes in neutrophils, but
possibly less ubiquitously than ACSL1, as suggested by narrower
range of response to pathogen-derived activators (Figure 4).
Figure 7 summarizes the points that have been inferred with
regards to regulation of ACSL1 and ACSL4 expression in
leukocytes and their involvement in sepsis pathogenesis. Figure 6
provides a first indication of the potential clinical relevance of the
phenomenon being described.
Follow on work should permit to characterize more precisely
the role of ACSL1 in neutrophils and sepsis. Gene silencing or
knock down technologies, such as siRNA or Crispr/Cas9 could
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for instance address the lack of specificity of triacsin C (since
it also inhibits other ACSL family members, including ACSL4).
The panel of stimuli employed in the experiment described in
Figure 4 could be employed in order to screen for pathway
specific alterations/defects. General activation and in particular
production of reactive oxygen species could be primarily be used
as readout. But use of omics scale profiling approaches would
also permit to obtain a more global perspective on the range
of effects ACSL1 may have on neutrophil function. In order to
investigate the role of ACSL1 in vivo an experiment would consist
in monitoring survival of Acsl1−/− mice [derived and employed
earlier in a different context (22, 27)] in a cecal ligation sepsis
model or following endotoxin challenge. Finally, it may also be
interesting to explore the possibility of ACSL1 and ACSL4 being
involved in responses to distinct bacterial species, as suggested
by the flagellin/flagellated bacteria bias observed in the ACSL4
response shown in Figure 4.
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Supplementary Figure 1 | Tissue restriction of ACSL family members. Relative
abundance levels of the 5 members of the ACSL family across 8 different human
tissues is shown is this figure. Expression data used to generate the plots were
obtained from the BioGPS dataset (21). Each family member is represented by a
different color: ACSL1 (red), ACSL2 (beige), ACSL4 (green), ACSL5 (blue), and
ACSL6 (purple). Predominance of a given color in a circle denotes predominance
of expression of the corresponding ACSL family member in the tissue in question.
Cord plots were generated using the circlize R package (121).
Supplementary Figure 2 | Abundance levels of a co-expressed geneset
comprising ACSL1 across leukocyte populations and disease states. A reference
public domain dataset was downloaded from GEO (GSE60424) in which RNAseq
profiles were generated for 6 leukocyte subsets (legend: cell types) isolated from
20 blood samples collected from healthy subjects and subjects with a wide range
of pathologies (legend: disease). Z-scores were computed from normalized
counts and displayed on a heatmap (blue/gray = low expression; yellow = high
expression. Samples were arranged according to grouping information and genes
were arranged based on similarities in patterns of expression across samples.
Supplementary Figure 3 | Correlation matrix for “inflammasome” and “fatty acid
metabolism” gene sets. Lists of genes known to be associated with
inflammasome and fatty acid metabolism were derived from targeted RT-PCR
panels (referenced in the text). ACSL1 was added to the inflammasome list. The
matrix represents degree of correlation calculated for each gene pair using the
septic plasma neutrophil exposure dataset (GSE49755).
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